# 2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.

> **NCT03988933** · PHASE2 · COMPLETED · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 1368 (actual)

## Conditions studied

- Latent Tuberculosis

## Interventions

- **DRUG:** Rifampin double dose
- **DRUG:** Rifampin triple dose
- **DRUG:** Rifampin standard dose

## Key facts

- **NCT ID:** NCT03988933
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-20
- **Primary completion:** 2023-01-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 1368 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03988933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03988933, "2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03988933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*